CB 103
Alternative Names: CB-103Latest Information Update: 19 Jan 2024
At a glance
- Originator Swiss Federal Institute of Technology - Lausanne
- Developer Cellestia Biotech
- Class Amines; Antineoplastics; Pyrimidines; Small molecules
- Mechanism of Action Notch signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Phase I/II Adenoid cystic carcinoma; Haematological malignancies; Solid tumours
- Phase I Graft-versus-host disease
Most Recent Events
- 11 Jan 2024 Cellestia Biotech plans a proof of concept clinical trial for Graft-versus-host disease
- 19 Dec 2023 Cellestia Biotech and MedSIR terminates the phase II CAILA trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO, Capsule), due to sponsor's decision (NCT04714619)
- 01 Jun 2023 Phase-I/II clinical trials in Adenoid cystic carcinoma (Late-stage disease, Recurrent, Combination therapy, Metastatic disease) in USA (PO) (NCT05774899)